Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Fungal and Parasitic Infections

Passive Immunization with Melanin-Binding Monoclonal Antibodies Prolongs Survival of Mice with Lethal Cryptococcus neoformans Infection

Ángel L. Rosas, Joshua D. Nosanchuk, Arturo Casadevall
Ángel L. Rosas
Department of Microbiology & Immunology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua D. Nosanchuk
Division of Infectious Diseases of the Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arturo Casadevall
Department of Microbiology & Immunology and
Division of Infectious Diseases of the Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.69.5.3410-3412.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Passive immunization with monoclonal antibodies (MAbs) to melanin prolonged the survival of and reduced the fungal burden inCryptococcus neoformans-infected mice in comparison to controls. MAbs to melanin reduced the growth rate of in vitro-melanizedC. neoformans cells, suggesting a new mechanism of antibody-mediated protection.

Cryptococcus neoformansis an encapsulated yeastlike fungus that has emerged as a leading pathogen in immunocompromised individuals, including 6 to 8% of patients with AIDS (reviewed in reference 3). There is strong evidence that C. neoformans synthesizes cell wall-associated melanin during infections (6, 7, 9). Antibodies to melanin are generated during cryptococcal infection (6). Melanins are thought to contribute to virulence by protecting C. neoformans against host effector mechanisms, such as macrophage-mediated phagocytosis, oxidants, and microbicidal peptides (reviewed in reference 1).

We have recently generated murine monoclonal antibodies (MAbs) to melanin and used them to study melanization of C. neoformansin vivo (7, 9). In this study we investigated whether the MAbs to melanin have protective efficacy against C. neoformans infections in mice. Our results indicate that the MAbs to melanin can prolong the survival of and reduce the fungal burden in lethally infected mice.

The data in this paper are from a thesis to be submitted byÁngel L. Rosas in partial fulfillment of the requirements for the degree of doctor of philosophy in the Sue Golding Graduate Division of Medical Sciences, Albert Einstein College of Medicine, Yeshiva University, Bronx, N.Y.

C. neoformans strain 24067 (serotype D) was obtained from the American Type Culture Collection (Rockville, Md.), and strain H99 (serotype A) was obtained from John Perfect (Durham, N.C.). C. neoformans cultures were grown in Sabouraud dextrose broth (Difco, Detroit, Mich.) for 2 days at 30°C in a rotary shaker at 150 rpm. Ten 8- to 10-week-old female C57BL/6 mice (National Cancer Institute, Rockville, Md.) per group were passively immunized with ascites containing 1 mg of MAb 6D2 or 11B11 and infected with strain 24067. Ascites from NSO, the nonproducing mouse myeloma fusion partner of the hybridomas, was used as a negative control. At 30 min after immunization, the mice were infected intravenously with 2 × 107 cells. Comparisons of survival of infected mice immunized with the MAbs to that of melanin- or NSO ascites-treated mice were analyzed using log rank analysis (SPSS Inc., Chicago, Ill.). P values of less than 0.05 were considered significant. The mice were housed in the animal facility of Albert Einstein College of Medicine, and all experimental procedures adhered to protocols approved by the Animal Care and Use Committee. Mice given MAb to melanin lived significantly longer than control mice ( P < 0.05 ; Fig.1A). The experiment was performed three times with similar results. A fourth experiment was done using mice infected intravenously with 2 × 105 cells of strain H99 and employing the immunoglobulin M (IgM) MAb 5C11 with specificity for mycobacterial lipoarabinomannan (3) as a negative control (Fig. 1B). Again, mice given MAb to melanin lived significantly longer than control mice given the irrelevant IgM.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

(A) Passive immunization with MAb 6D2 or 11B11 to melanin prolongs the survival of mice infected with C. neoformans strain 24067 in comparison to mice given NSO ascites (10 mice per group). (B) Passive immunization with MAb 6D2 or 11B11 prolongs the survival of mice infected with C. neoformans strain H99 in comparison to mice given MAb 5B11 with specificity for mycobacterial lipoarabinomannan (10 mice per group).

C. neoformans infections were also performed to determine whether immunization with the MAbs to melanin reduced the fungal burden in infected mice. Ten female C57BL/6 mice per group were immunized and infected as described above. At day 7 after infection, the surviving mice were killed, and the lungs and brains were collected and homogenized by mechanical grinding in 5 ml of phosphate-buffered saline (PBS, pH 7.4) to recover the fungal cells. Cells were then plated on Sabouraud dextrose agar (Difco) for 3 days at 30°C. Pvalues were calculated with Student's t test using Primer of Statistics: The Program, version 3.0 (McGraw-Hill Inc., New York, N.Y.) for comparison of fungal burden in mice immunized with MAb 6D2 or 11B11 to that in mice treated with NSO ascites. Pvalues of less than 0.05 were considered significant. Mice given MAbs to melanin had significantly lower fungal burdens than control mice ( P < 0.001 ; Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Effect of melanin-binding antibody on the growth ofC. neoformans in vitro

To investigate whether the MAbs to melanin had an effect on melanizedC. neoformans cells, C. neoformans 24067 cells were grown in minimal medium (15 mM dextrose, 10 mM MgSO4, 29.4 mM KH2PO4, 13 mM glycine, and 3 μM vitamin B1 [pH 5.5]) with or without 1 mMl-3,4-dihydroxyphenylalanine (l-dopa) (Sigma Chemical Co., St. Louis, Mo.) for 7 days at 30°C. l-Dopa served as the substrate for melanization. Cells were then collected, washed, and suspended in minimal medium with l-dopa. A suspension containing 5,000 melanized or nonmelanized fungal cells (100 μl) was plated in 96-well tissue culture plates in duplicate (Becton Dickinson, Cockeysville, Md.) in the presence of ascites containing MAb 6D2 or 11B11 (100 to 0.78 μg/ml). Ascites with MAb 5C11 (100 μg/ml) to mycobacterial lipoarabinomannan served as a negative control. After 2 days of incubation at 30°C, the cells were collected, diluted 1:10 in PBS, and counted using a hemacytometer. The counting was facilitated by the fact that MAbs to melanin do not cause agglutination of C. neoformans (9). Incubation of the MAbs to melanin with in vitro-melanized C. neoformans 24067 significantly reduced the growth rate of the fungal cells in comparison to growth with MAb 5C11 (Fig. 2). No differences in growth rate were observed with nonmelanized C. neoformans24067 cells incubated with the MAbs to melanin or MAb 5C11 (data not shown). This result is of particular interest because previous studies have shown that C. neoformans can grow on purified capsule-binding MAbs (2). In a similar experiment, in vitro-melanized C. neoformans 24067 was incubated with the melanin-binding peptide 4B4 (YERKFWHGRH) or the control peptide P601G (DGASYSWMYGA) (6). A significant reduction in the growth rate of melanized C. neoformans was observed when the cells were incubated with the melanin-binding peptide 4B4 in comparison to cells grown with the control peptide (Fig. 2). The growth experiments with the MAbs and the melanin-binding peptide were performed three times with similar results. Hence, it appears that binding of melanin-binding protein to melanized cells, whether in the form of antibody or peptide, can inhibit melanized cell growth.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Incubation of MAbs to melanin or melanin-binding peptide reduces the growth rate of in vitro-melanized C. neoformanscells in comparison to growth with MAb 5C11 or a control peptide. Data points represent the mean of measurements for two wells for each concentration from a single experiment.

In summary, the results from these experiments demonstrate that the MAbs to melanin have protective efficacy against C. neoformans infections in mice. The observation that MAbs to melanin mediate protection against C. neoformans infection is consistent with and supportive of the premise that the fungus melanizes in tissue (1). C. neoformans is surrounded by a polysaccharide capsule (reviewed in reference4), and binding of the MAbs to the melanin occurs in the cell wall area (7, 9). The MAbs to melanin do not induce phagocytosis of in vitro-melanized C. neoformans cells by the murine macrophage-like cell line J774.16 (unpublished observations), and therefore it is unlikely that the mechanism of protection involves induction of phagocytosis of the fungus by host effector cells. The MAbs to melanin are not agglutinating, and this excludes yeast cell clumping as a mechanism for the effects observed in in vitro and in vivo. The MAbs to melanin and the melanin-binding peptides can diffuse through the capsule to bind at the cell surface (6, 9), and they both were able to reduce the growth rate of melanized C. neoformans cells in vitro. This suggests a mechanism of MAb-mediated protection by which binding of the MAbs to melanized C. neoformans in vivo could alter the properties of the melanin in the cell wall and thereby interfere with cell growth and replication in the presence of this polymer. This mechanism may be similar to that recently described for antibodies to glucosylceramide, which also inhibited C. neoformans growth after binding to the cell wall (8). Furthermore, our results suggest that antibody responses to melanin elicited by C. neoformans infection may be useful in host defense.

ACKNOWLEDGMENTS

Arturo Casadevall is suppoorted by NIH grants AI33774, AI13342, and HL59842 and is the recipient of a Burroughs Wellcome Fund Scholar Award in Experimental Therapeutics. Ángel L. Rosas is supported by NIH grant 5T32GM07491. Joshua D. Nosanchuk is supported by NIH grant AI01489.

Notes

Editor: T. R. Kozel

FOOTNOTES

    • Received 21 December 2000.
    • Returned for modification 29 January 2001.
    • Accepted 15 February 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Casadevall A.,
    2. Rosas Á. L.,
    3. Nosanchuk J. D.
    Melanin and virulence in Cryptococcus neoformans.Curr. Opn. Microbiol.32000354358
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Chen L.,
    2. Blank E. S.,
    3. Casadevall A.
    Extracellular proteinase activity of Cryptococcus neoformans.Clin. Diagn. Lab. Immunol.31996570574
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Glatman-Freedman A.,
    2. Martin J. M.,
    3. Rifka P. F.,
    4. Bloom B. R.,
    5. Casadevall A.
    Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria.J. Clin. Microbiol.34199627952802
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kozel T. R.
    Virulence factors of Cryptococcus neoformans.Trends Microbiol.31995295299
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.
    1. Mitchell T. G.,
    2. Perfect J. R.
    Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans.Clin. Microbiol. Rev.81995515548
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Nosanchuk J. D.,
    2. Valadon P.,
    3. Feldmesser M.,
    4. Casadevall A.
    Melanization of Cryptococcus neoformans in murine infection.Mol. Cell. Biol.191999745750
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Nosanchuk J. D.,
    2. Rosas A. L.,
    3. Lee S. C.,
    4. Casadevall A.
    Melanisation of Cryptococcus neoformans in human brain tissue.Lancet355200020492050
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Rodrigues M. L.,
    2. Travassos L. R.,
    3. Miranda K. R.,
    4. Franzen A. J.,
    5. Rozenthal S.,
    6. de Souza W.,
    7. Alviano C. S.,
    8. Barreto-Berger E.
    Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth.Infect. Immun.68200070497060
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Rosas Á. L.,
    2. Nosanchuk J. D.,
    3. Feldmesser M.,
    4. Cox G. M.,
    5. McDade H. C.,
    6. Casadevall A.
    Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents.Infect. Immun.68200028452853
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Passive Immunization with Melanin-Binding Monoclonal Antibodies Prolongs Survival of Mice with Lethal Cryptococcus neoformans Infection
Ángel L. Rosas, Joshua D. Nosanchuk, Arturo Casadevall
Infection and Immunity May 2001, 69 (5) 3410-3412; DOI: 10.1128/IAI.69.5.3410-3412.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Passive Immunization with Melanin-Binding Monoclonal Antibodies Prolongs Survival of Mice with Lethal Cryptococcus neoformans Infection
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Passive Immunization with Melanin-Binding Monoclonal Antibodies Prolongs Survival of Mice with Lethal Cryptococcus neoformans Infection
Ángel L. Rosas, Joshua D. Nosanchuk, Arturo Casadevall
Infection and Immunity May 2001, 69 (5) 3410-3412; DOI: 10.1128/IAI.69.5.3410-3412.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • Notes
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Monoclonal
cryptococcosis
Melanins

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522